ArticleBMC medical imaging2025
The feasibility of the radiomics models for tumor-infiltrating lymphocytes level prediction in breast cancer based on dynamic contrast-enhanced MRI.
Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Toward genomic personalization of breast cancer radiotherapy: foundations, challenges, and a roadmap for clinical integration.Breast (Edinburgh, Scotland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundDetermining tumor-infiltrating lymphocyte (TIL) expression in breast cancer prior to treatment initiation is of considerable clinical significance. MRI demonstrates potential as a valuable adjunct to histopathological assessment. This study investigated the feasibility of developing a radiomics-based predictive model incorporating MRI and clinical features to determine TIL levels in breast cancer.
methodsThis multicenter retrospective cohort study enrolled 501 patients across two institutions. A total of 453 patients were utilized for model development, comprising a training cohort (n = 317) and internal validation cohort (n = 136), while 48 patients from an external center constituted the independent test cohort. Radiomics features were extracted and subsequently selected using ANOVA and LASSO regression. Logistic regression algorithms were employed for model construction. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the discriminative performance between low-level and intermediate-high-level TILs, comparing the radiomics model with the integrated clinical-radiomics model.
resultsThe MRI-based radiomics model demonstrated robust performance for TIL level prediction across both training and internal validation cohorts, achieving areas under the curve (AUC) of 0.810 (95% confidence interval [CI]: 0.781-0.874) and 0.756 (95% CI: 0.676-0.837), respectively. The integrated clinical-radiomics model exhibited superior discriminative performance with AUCs of 0.828 (95% CI: 0.762-0.858) and 0.824 (95% CI: 0.755-0.893) for the training and validation cohorts, respectively. In the external independent test cohort, the radiomics model and integrated model achieved AUCs of 0.704 (95% CI: 0.558-0.850) and 0.767 (95% CI: 0.633-0.901), respectively.
conclusionsRadiomics features extracted from dynamic contrast-enhanced MRI, when integrated with clinical characteristics, represent a promising non-invasive approach for predicting TIL levels in breast cancer. This methodology may facilitate clinical decision-making through enhanced pretreatment tumor characterization without requiring invasive tissue sampling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.